Literature DB >> 8625224

Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes.

A E Chucrallah1, S A Stass, Y O Huh, M Albitar, H M Kantarjian.   

Abstract

BACKGROUND: There have been published reports on cytogenetic, immunophenotypic, and molecular changes at relapse in childhood acute lymphoblastic leukemia (ALL) including lineage switch and secondary leukemia. There are limited data, however, on the cytogenetic, immunophenotypic, and molecular parameters of adult ALL at relapse. Because, as in children, the cytogenetic and/or immunophenotypic changes observed in adult ALL at relapse may have prognostic significance, the authors investigated the significance of such changes.
METHODS: Fifty-three patients with relapsed adult ALL for whom cytogenetic, immunophenotypic, and/or molecular analyses were performed at diagnosis and at relapse were studied. Changes in any of the parameters at relapse were correlated with total survival and survival from the time of relapse.
RESULTS: Of the 32 patients for whom cytogenetic studies were performed at relapse, 21 (66%) showed clonal cytogenetic changes, 40% of which were clonal evolution. None of these cases, however, showed two entirely different abnormal karyotypes at diagnosis and at relapse. The immunophenotypes showed occasional gain or loss of one or two surface markers, and the molecular genetic configurations for JH, JK, and the T-cell receptor beta were stable throughout the evolution of the disease. Patients with clonal evolution had a shorter overall survival than the rest of the group (P = 0.02). This difference, however, was not significant with respect to survival measured from the time of relapse.
CONCLUSIONS: The most frequent changes in the biologic profile of adult ALL at relapse are shifts in the karyotype, with or without clonal evolution. Clonal evolution detected at relapse is associated with a higher frequency of unfavorable karyotypes at diagnosis and with a worse overall prognosis. However, survival from the time of relapse is similar in patients with and without clonal evolution.

Entities:  

Mesh:

Year:  1995        PMID: 8625224     DOI: 10.1002/1097-0142(19950915)76:6<985::aid-cncr2820760611>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Yi-Fen Shi; Na Wang; Zi-Yang Huang; Rong-Rong Chen; Yi-Sha Huang; Yi-Yi Zhu; Chong-Yun Xing; Bin Liang; Kang Yu; Jian-Hua Feng
Journal:  Cancer Manag Res       Date:  2020-08-10       Impact factor: 3.989

Review 2.  Immunologic monitoring in adults with acute lymphoblastic leukemia.

Authors:  María-Belén Vidriales; Alberto Orfao; Jesús F San-Miguel
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease.

Authors:  Hyojeong Kim; Young Mi Seol; Moo-Kon Song; Young Jin Choi; Ho-Jin Shin; Sang Hyuk Park; Eun Yup Lee; Joo-Seop Chung
Journal:  Blood Res       Date:  2016-09-23

4.  Hard-wired heterogeneity in blood stem cells revealed using a dynamic regulatory network model.

Authors:  Nicola Bonzanni; Abhishek Garg; K Anton Feenstra; Judith Schütte; Sarah Kinston; Diego Miranda-Saavedra; Jaap Heringa; Ioannis Xenarios; Berthold Göttgens
Journal:  Bioinformatics       Date:  2013-07-01       Impact factor: 6.937

5.  Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients.

Authors:  Yundeok Kim; Jieun Jang; Shin Yong Hyun; Dohyu Hwang; Soo Jeong Kim; Jin Seok Kim; Jun-Won Cheong; Yoo Hong Min
Journal:  Blood Res       Date:  2013-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.